The Top Line Breaking down the 55 new drug approvals of 2024
Jan 10, 2025
The FDA's 2024 drug approvals spotlight the impressive entry of small biotech firms, overshadowing big pharma. Noteworthy innovations include a new schizophrenia treatment and therapies for leukemia and COPD. The approval landscape reflects a shift, with fewer nods to large companies compared to previous years. New gene and cell therapies emerge, promising significant market impact. As the pharmaceutical realm evolves, these developments herald a new era of patient care and treatment possibilities.
AI Snips
Chapters
Transcript
Episode notes
Small Biotechs Gained Ground
- Small companies drove a much larger share of FDA approvals in 2024 versus 2023.
- Approvals by sponsors with >=$3B revenue fell from 63% in 2023 to 42% in 2024.
Big Pharma Pullback Shifted Roles
- Big pharmas are cutting costs and narrowing focus, leaving commercialization to smaller biotechs.
- Fewer co-sponsored approvals occurred in 2024 (2) versus 2023 (11), reflecting that pullback.
Ionis Decides To Self-Launch
- Ionis chose to commercialize a newly approved drug for FCS itself instead of partnering.
- The company plans multiple self-launches through 2027 and called it a pivotal moment.